Threonine

Threonine

SCHEMBL527856

CC(O)C(N)C(=O)O.NC(CO)C(=O)O.O=C(O)C1CCCN1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Threonine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRCP P42785 1/20 0.32
NOS2 P35228 2/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
THRB P10828 1/20 0.31
ALOX15 P16050 1/20 0.31
CYP2C19 P33261 1/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GRIA1 P42261 1/20 0.31
GRIA2 P42262 1/20 0.31
GRIA3 P42263 1/20 0.31
GRIA4 P48058 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Threonine SCHEMBL27562283 1.00 PRCP (0.32) PRCPNOS2NOS3NOS1DPP7
Threonine SCHEMBL8815158 1.00 PRCP (0.32) PRCPNOS2NOS3NOS1DPP7
Threonine SCHEMBL27592182 1.00 PRCP (0.32) PRCPNOS2NOS3NOS1DPP7
Threonine SCHEMBL527858 1.00 PRCP (0.32) PRCPNOS2NOS3NOS1DPP7
Threonine SCHEMBL28072332 0.95
Threonine SCHEMBL6520771 0.93
Asparagine SCHEMBL28801819 0.93 CD274 (0.33) NOS2NOS3NOS1GRIA1GRIA2
Threonine SCHEMBL6520767 0.93
D-Glutamate SCHEMBL27779763 0.92 GRM8 (0.40) DPP7KMT2ACYP1A2ALOX15GRIN2D
Glutamine SCHEMBL27823468 0.91 ALOX15 (0.41) KMT2ACYP1A2ALOX15GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4361279-A2 PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED CD163 GENES The Curators of the University of Missouri (US) 2024-05-01 EP disclosed
US-20240122164-A1 PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED CD163 GENES THE CURATORS OF THE UNIVERSITY OF MISSOURI 2024-04-18 US disclosed
EP-3331355-B1 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV)-RESISTANT PORCINE AND CELLS HAVING MODIFIED CD163 GENES UNIV MISSOURI (US) 2024-04-03 EP disclosed
US-20230272397-A1 METHODS FOR IMPROVING THE HEALTH OF PORCINE SPECIES BY TARGETED INACTIVATION OF CD163 GENUS PLC (US) 2023-08-31 US disclosed
EP-4145991-A1 METHODS FOR IMPROVING THE HEALTH OF PORCINE SPECIES BY TARGETED INACTIVATION OF CD163 Genus Plc (GB) 2023-03-15 EP disclosed
US-11535850-B2 Methods for improving the health of porcine species by targeted inactivation of CD163 GENUS PLC (US) 2022-12-27 US disclosed
US-20220135976-A1 METHODS FOR IMPROVING THE HEALTH OF PORCINE SPECIES BY TARGETED INACTIVATION OF CD163 GENUS PLC (US) 2022-05-05 US disclosed
US-20220015340-A1 METHODS FOR PROTECTING PORCINE FETUSES FROM INFECTION WITH PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) THE CURATORS OF THE UNIVERSITY OF MISSOURI 2022-01-20 US disclosed
US-11208659-B2 Pig with a genetically modified CD163 gene resistant to PRRSv GENUS PLC (US) 2021-12-28 US disclosed
WO-2021224599-A1 METHODS FOR IMPROVING THE HEALTH OF PORCINE SPECIES BY TARGETED INACTIVATION OF CD163 GENUS PLC (US) 2021-11-11 WO disclosed
US-8877896-B2 Compositions, methods and kits for modeling, diagnosing, and treating complement disorders TUFTS UNIVERSITY (US) 2014-11-04 US disclosed
US-20130149373-A1 Compositions, methods and kits for modeling, diagnosing, and treating complement disorders TUFTS UNIVERSITY (US) 2013-06-13 US disclosed
WO-2012016162-A2 COMPOSITIONS, METHODS AND KITS FOR MODELING, DIAGNOSING, AND TREATING COMPLEMENT DISORDERS TUFTS UNIVERSITY (US) 2012-02-02 WO disclosed
US-7485712-B2 Protein kinase (NPK-110) MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2009-02-03 US disclosed
EP-0791067-B1 PROTEIN KINASE NPK-110 MAX PLANCK GESELLSCHAFT (DE) 2008-12-17 EP disclosed
US-20040038361-A1 Novel protein kinase (NPK-110) MANDELKOW ECKHARD (DE) 2004-02-26 US disclosed
US-6579691-B1 DNA sequence encoding a neuronal protein kinase (NPK) which phosphorylates tau proteins as well as other microtubule associated proteins (MAPs) in positions crucial for the binding to microtubules, alzheimers disease, antitumor MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN, E.V. (DE) 2003-06-17 US disclosed
CN-1327388-A Modified antibodies of induced anti-idiotype reaction enhancement EURO CELTIQUE SA (BM) 2001-12-19 CN disclosed
EP-0791067-A2 PROTEIN KINASE NPK-110 MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) 1997-08-27 EP disclosed
WO-1996013592-A2 PROTEIN KINASE NPK-110 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1996-05-09 WO disclosed